Kazuhiko Nakagawa

List of Publications by Year
in descending order

166	24,228	44444 50	8627 151
papers	citations	h-index	g-index

168	168	168	18146
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Trastuzumab Deruxtecan in HER2-Mutant Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2022, 386, 241-251.	13.9	393
2	Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Nonâ€“Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). Clinical Lung Cancer, 2022, 23, e257-e263.	1.1	10
3	Realâ€world data on NGS using the Oncomine DxTT for detecting genetic alterations in nonâ€smallâ€cell lung cancer: WJOG13019L. Cancer Science, 2022, 113, 221-228.	1.7	31
4	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Nonâ€“Small-Cell Lung Cancer With EGFR Mutation (IMPACT). Journal of Clinical Oncology, 2022, 40, 231-241.	0.8	61
5	Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naÂ¨ve advanced non-small-cell lung cancer. European Journal of Cancer, 2022, 161, 44-54.	1.3	7
6	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
7	RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Drug Safety, 2022, 45, 45-64.	1.4	6
8	A Randomized Phase II Study Comparing Nivolumab with Carboplatinâ€“Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research, 2022, 28, 893-902.	3.2	35
9	RELAY+: Exploratory Study of Ramucirumab PlusÂGefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC. JTO Clinical and Research Reports, 2022, 3, 100303.	0.6	1
10	HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 390-403.	3.2	34
11	Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Nonâ€“Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). Lung Cancer, 2022, 168, 38-45.	0.9	5
12	The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.. Journal of Clinical Oncology, 2022, 40, e21177-e21177.	0.8	1
13	Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).. Journal of Clinical Oncology, 2022, 40, e21175-e21175.	0.8	0
14	EORTC-1416-LCG/ETOP 8-15 â€“ PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.. Journal of Clinical Oncology, 2022, 40, 8512-8512.	0.8	14
15	Nivolumab Retreatment in Nonâ€“Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clinical Cancer Research, 2022, 28, 3207-3213.	3.2	7
16	RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposureâ€“response relationship. Cancer Chemotherapy and Pharmacology, 2022, 90, 137-148.	1.1	4
17	Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. European Journal of Cancer, 2022, 171, 259-268.	1.3	19
18	Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 ÂJapan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. International Journal of Clinical Oncology, 2021, 26, 1-17.	1.0	56

#	Article	IF	Citations
19	Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies. Japanese Journal of Clinical Oncology, 2021, 51, 106-113.	0.6	8
20	Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 205-215.	0.5	149
21	Phase I/ II Study of Cisplatin plus Nabâ€Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Nonâ€Small Cell Lung Cancer. Oncologist, 2021, 26, 19.	1.9	1
22	The patientâ€™s perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. Future Oncology, 2021, 17, 783-794.	1.1	0
23	Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. Journal of Thoracic Oncology, 2021, 16, 452-463.	0.5	51
24	Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. Future Oncology, 2021, 17, 103-115.	1.1	1
25	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs, 2021, 81, 257-266.	4.9	57
26	Predicting osimertinibâ€treatment outcomes through EGFR mutantâ€fraction monitoring in the circulating tumor DNA of EGFR T790Mâ€positive patients with nonâ€small cell lung cancer (WJOG8815L). Molecular Oncology, 2021, 15, 126-137.	2.1	12
27	Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study. JTO Clinical and Research Reports, 2021, 2, 100135.	0.6	9
28	Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790Mâ€“Mutated Nonâ€“Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitor. JAMA Oncology, 2021, 7, 386.	3.4	108
29	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer, 2021, 154, 176-185.	0.9	18
30	Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort.. Journal of Clinical Oncology, 2021, 39, 9042-9042.	0.8	3
31	A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).. Journal of Clinical Oncology, 2021, 39, 9037-9037.	0.8	5
32	Challenges in lung cancer multidisciplinary collaboration experienced by specialists in four countries.. Journal of Clinical Oncology, 2021, 39, e23002-e23002.	0.8	0
33	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respiratory Medicine,the, 2021, 9, 613-621.	5.2	44
34	Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma. JTO Clinical and Research Reports, 2021, 2, 100178.	0.6	4
35	Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. JTO Clinical and Research Reports, 2021, 2, 100171.	0.6	5
36	Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. Cancer Biomarkers, 2021, 31, 119-126.	0.8	1

#	Article	IF	Citations
37	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5258-5271.	3.2	23
38	Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study. JTO Clinical and Research Reports, 2021, 2, 100184.	0.6	8
39	KRAS Inhibitor Resistance in MET-Amplified KRASG12C Nonâ€“Small Cell Lung Cancer Induced By RAS- and Nonâ€“RAS-Mediated Cell Signaling Mechanisms. Clinical Cancer Research, 2021, 27, 5697-5707.	3.2	42
40	Firstâ€line pembrolizumab vs chemotherapy in metastatic nonâ€smallâ€cell lung cancer: KEYNOTEâ€024 Japan subset*. Cancer Science, 2021, 112, 5000-5010.	1.7	6
41	Realâ€world safety of nivolumab in patients with nonâ€smallâ€cell lung cancer in Japan: Postmarketing surveillance. Cancer Science, 2021, 112, 4692-4701.	1.7	14
42	Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A). Japanese Journal of Clinical Oncology, 2021, 51, 685-692.	0.6	1
43	Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis. Frontiers in Oncology, 2021, 11, 763468.	1.3	10
44	Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study. Drugs in R and D, 2021, 21, 65-78.	1.1	1
45	Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Management and Research, 2021, Volume 13, 9167-9173.	0.9	5
46	Combination therapy with PD-1 or PD-L1 inhibitors for cancer. International Journal of Clinical Oncology, 2020, 25, 818-830.	1.0	86
47	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020, 139, 195-199.	0.9	100
48	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: COMPASS (WJOG5610L). Journal of Clinical Oncology, 2020, 38, 793-803.	0.8	28
49	Ramucirumab or placebo plus erlotinib in EGFRâ€mutated, metastatic nonâ€smallâ€cell lung cancer: East Asian subset of RELAY. Cancer Science, 2020, 111, 4510-4525.	1.7	17
50	Severe Immune-Related Hepatitis Treated With Plasma Exchange. Journal of Thoracic Oncology, 2020, 15, e39-e42.	0.5	3
51	Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?. Translational Lung Cancer Research, 2020, 9, 1617-1622.	1.3	2
52	Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Current Medical Research and Opinion, 2020, 36, 1667-1675.	0.9	11
53	Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model. Journal of Clinical Medicine, 2020, 9, 4050.	1.0	2
54	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>â€158 and <scp>KEYNOTE</scp>â€028 studies. International Journal of Cancer, 2020, 147, 2190-2198.	2.3	288

#	Article	IF	Citations
55	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, e196828.	3.4	48
56	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. BMC Cancer, 2020, 20, 103.	1.1	14
57	Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2037-2046.	3.2	142
58	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 661.	3.4	446
59	Safety and efficacy of firstâ€line dacomitinib in Japanese patients with advanced nonâ€small cell lung cancer. Cancer Science, 2020, 111, 1724-1738.	1.7	20
60	NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.. Journal of Clinical Oncology, 2020, 38, 106-106.	0.8	11
61	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.. Journal of Clinical Oncology, 2020, 38, 9504-9504.	0.8	91
62	RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9564-9564.	0.8	2
63	NGSCUP: Phase II trial of site-specific treatment based on gene expression and mutation profiling by next generation sequencing (NGS) for patients (pts) with cancer of unknown primary site (CUP).. Journal of Clinical Oncology, 2020, 38, e15577-e15577.	0.8	1
64	RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).. Journal of Clinical Oncology, 2020, 38, 9527-9527.	0.8	1
65	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Future Oncology, 2019, 15, 2795-2805.	1.1	27
66	Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. Lung Cancer, 2019, 135, 145-150.	0.9	18
67	Threeâ€year followâ€up results from phase II studies of nivolumab in Japanese patients with previously treated advanced nonâ€small cell lung cancer: Pooled analysis of ONOâ€4538â€05 and ONOâ€4538â€06 studies. Cancer Medicine, 2019, 8, 5183-5193.	1.3	13
68	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	5.1	418
69	A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. Scientific Reports, 2019, 9, 11340.	1.6	12
70	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
71	Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. Oncogenesis, 2019, 8, 54.	2.1	12
72	Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u>ulticenter, Op<u>e</u>n-label, Single-a<u>r</u>m, Japanese Phase II study in Mal<u>i</u>gnant Pleural Meso<u>t</u>helioma (MERIT). Clinical Cancer Research, 2019, 25, 5485-5492.	3.2	191

#	Article	IF	Citations
73	New Era for Next-Generation Sequencing in Japan. Cancers, 2019, 11, 742.	1.7	22
74	Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncology, 2019, 15, 1481-1491.	1.1	11
75	<scp>KEYNOTE</scp>â€025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1â€“positive advanced nonâ€“smallâ€cell lung cancer. Cancer Science, 2019, 110, 1012-1020.	1.7	40
76	Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. International Journal of Clinical Oncology, 2019, 24, 485-493.	1.0	4
77	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 2019, 132, 126-131.	0.9	26
78	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). Lung Cancer, 2019, 131, 128-133.	0.9	18
79	Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Scientific Reports, 2019, 9, 19501.	1.6	12
80	Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Japanese Journal of Clinical Oncology, 2019, 49, 29-36.	0.6	101
81	First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer. Cancer Treatment and Research Communications, 2019, 18, 100113.	0.7	9
82	First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?. International Journal of Molecular Sciences, 2019, 20, 146.	1.8	118
83	Mutational activation of the epidermal growth factor receptor downâ€regulates major histocompatibility complex class I expression via the extracellular signalâ€regulated kinase in nonâ€“small cell lung cancer. Cancer Science, 2019, 110, 52-60.	1.7	31
84	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. Journal of Clinical Investigation, 2019, 130, 374-388.	3.9	43
85	Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.. Journal of Clinical Oncology, 2019, 37, 4079-4079.	0.8	94
86	RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9000-9000.	0.8	23
87	A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).. Journal of Clinical Oncology, 2019, 37, 9003-9003.	0.8	3
88	Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) Â± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. Journal of Clinical Oncology, 2019, 37, 9016-9016.	0.8	20
89	Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).. Journal of Clinical Oncology, 2019, 37, 9031-9031.	0.8	8
90	Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naÃ¯ve ALK-positive non-small cell lung cancer (ALK+ NSCLC).. Journal of Clinical Oncology, 2019, 37, 9092-9092.	0.8	14

#	Article	IF	Citations
91	A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).. Journal of Clinical Oncology, 2019, 37, TPS9125-TPS9125.	0.8	3
92	The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naÃ¯ve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).. Journal of Clinical Oncology, 2019, 37, 9038-9038.	0.8	0
93	Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2019, 37, 8557-8557.	0.8	2
94	Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L).. Journal of Clinical Oncology, 2019, 37, e20531-e20531.	0.8	0
95	Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Japanese Journal of Clinical Oncology, 2018, 48, 367-375.	0.6	26
96	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer, 2018, 117, 14-19.	0.9	63
97	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Nonâ€“Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clinical Lung Cancer, 2018, 19, 213-220.e4.	1.1	13
98	Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2018, 121, 37-40.	0.9	62
99	Sterilized talc pleurodesis for malignant pleural effusions: a Phase II study for investigational new drug application in Japan. Japanese Journal of Clinical Oncology, 2018, 48, 376-381.	0.6	3
100	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology, 2018, 36, 2244-2250.	0.8	361
101	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3290-3297.	0.8	515
102	Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2018, 106, 1018-1024.	0.7	8
103	A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L. British Journal of Cancer, 2018, 119, 675-682.	2.9	32
104	Prognostic value â€‹of Lung Cancer Subscale in older patients with advanced non-small cell lung cancer: An integrated analysis of JCOG0207 and JCOG0803/WJOG4307L (JCOG1414A). Journal of Geriatric Oncology, 2018, 9, 583-588.	0.5	4
105	<scp>ASP</scp>8273 tolerability and antitumor activity in tyrosine kinase inhibitorâ€naÃ¯ve Japanese patients with <scp>EGFR</scp> mutationâ€positive nonâ€small‐cell lung cancer. Cancer Science, 2018, 109, 2532-2538.	1.7	10
106	An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy. Cancer Chemotherapy and Pharmacology, 2018, 82, 685-694.	1.1	3
107	A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Breast, 2018, 40, 67-75.	0.9	34
108	Clinical activity of <scp>ASP</scp>8273 in Asian patients with nonâ€smallâ€cell lung cancer with <scp>EGFR</scp> activating and T790M mutations. Cancer Science, 2018, 109, 2852-2862.	1.7	15

#	Article	IF	Citations
109	Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.. Journal of Clinical Oncology, 2018, 36, 9004-9004.	0.8	9
110	Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2. Oncotarget, 2018, 9, 21132-21140.	0.8	24
111	Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer. Lung Cancer, 2017, 105, 1-6.	0.9	21
112	Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet, The, 2017, 390, 29-39.	6.3	753
113	Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 489-495.	1.1	25
114	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutationâ€“Positive Nonsquamous Nonâ€“Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. Clinical Lung Cancer, 2017, 18, 719-723.	1.1	13
115	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Journal of the National Cancer Institute, 2017, 109, .	3.0	196
116	Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. Japanese Journal of Clinical Oncology, 2017, 47, 618-624.	0.6	14
117	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 1454-1466.	5.1	877
118	Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 96-99.	1.1	10
119	Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Nonâ€“Small-Cell Lung Cancer: AF-001JP. Journal of Clinical Oncology, 2017, 35, 1515-1521.	0.8	63
120	Bevacizumab beyond disease progression after firstâ€line treatment with bevacizumab plus chemotherapy in advanced nonsquamous nonâ€“small cell lung cancer (<scp>W</scp>est) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 T trial. Cancer, 2016, 122, 1050-1059.	2.0	35
121	<scp>FGFR</scp> gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer Science, 2016, 107, 1667-1676.	1.7	31
122	Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Journal of Clinical Oncology, 2016, 34, 3248-3257.	0.8	130
123	A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer, 2016, 99, 186-193.	0.9	88
124	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Japanese Journal of Clinical Oncology, 2016, 46, 462-467.	0.6	54
125	A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer. Medical Oncology, 2016, 33, 2.	1.2	18
126	Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. International Journal of Clinical Oncology, 2016, 21, 1-12.	1.0	58

#	Article	IF	Citations
127	Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 346-352.	0.5	35
128	Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer, 2015, 88, 275-281.	0.9	36
129	Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L. Journal of Clinical Oncology, 2015, 33, 575-581.	0.8	109
130	Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter. Oncology Letters, 2015, 9, 405-410.	0.8	5
131	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology, The, 2015, 16, 990-998.	5.1	353
132	Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 2015, 88, 74-79.	0.9	157
133	A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer. BMC Research Notes, 2015, 8, 100.	0.6	4
134	A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 1058-1067.	1.2	13
135	The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget, 2015, 6, 33602-33611.	0.8	53
136	The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget, 2014, 5, 11847-11856.	0.8	61
137	Targeting MET Amplification as a New Oncogenic Driver. Cancers, 2014, 6, 1540-1552.	1.7	96
138	First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 2014, 371, 2167-2177.	13.9	2,808
139	Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respiratory Investigation, 2014, 52, 339-347.	0.9	3
140	Final safety and efficacy of erlotinib in the phase 4 <scp>POLARSTAR</scp> surveillance study of 10Â708 Japanese patients with nonâ€smallâ€cell lung cancer. Cancer Science, 2014, 105, 1584-1590.	1.7	67
141	Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509. Journal of Clinical Oncology, 2014, 32, 1262-1268.	0.8	66
142	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncology, The, 2014, 15, 1236-1244.	5.1	678
143	The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, e19082-e19082.	0.8	2
144	Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget, 2014, 5, 2293-2304.	0.8	32

#	Article	IF	Citations
145	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naÃ¯ve patients with advanced nonsquamous non-small-cell lung cancer. Investigational New Drugs, 2013, 31, 1275-1282.	1.2	38
146	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1â€“2 study. Lancet Oncology, The, 2013, 14, 590-598.	5.1	555
147	Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	13.9	3,181
148	Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405). Japanese Journal of Clinical Oncology, 2013, 43, 664-668.	0.6	38
149	MET amplification as a potential therapeutic target in gastric cancer. Oncotarget, 2013, 4, 9-17.	0.8	82
150	Phase I dose finding study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, alone or in combination with paclitaxel in Japanese patients.. Journal of Clinical Oncology, 2013, 31, e13501-e13501.	0.8	0
151	Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification. Molecular Cancer Therapeutics, 2012, 11, 1557-1564.	1.9	75
152	Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Nonâ€“Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR). Journal of Thoracic Oncology, 2012, 7, 1296-1303.	0.5	73
153	Perspectives in drug development for cancer therapy in Asia. Chinese Clinical Oncology, 2012, 1, 17.	0.4	1
154	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine, 2011, 3, 99ra86.	5.8	543
155	MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations. Journal of Thoracic Oncology, 2011, 6, 1624-1631.	0.5	122
156	Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics, 2010, 9, 2825-2833.	1.9	91
157	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-NaÃ¯ve Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. Journal of Clinical Oncology, 2010, 28, 5240-5246.	0.8	161
158	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128.	5.1	3,794
159	Interstitial Lung Disease in Japanese Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1348-1357.	2.5	428
160	Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients. Japanese Journal of Clinical Oncology, 2008, 38, 339-346.	0.6	22
161	Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors. Japanese Journal of Clinical Oncology, 2008, 39, 116-123.	0.6	18
162	Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study. Journal of Thoracic Oncology, 2008, 3, 1439-1445.	0.5	73

#	Article	IF	Citations
163	Clinical development of EGFR-tyrosine kinase inhibitors in Japan. Cancer Chemotherapy and Pharmacology, 2006, 58, 33-37.	1.1	1
164	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2003, 21, 2237-2246.	0.8	2,822
165	Phase I and Pharmacologic Study of Docetaxel and Irinotecan in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2000, 18, 2996-3003.	0.8	38
166	Two cases of portal-systemic shunts demonstrated by portal venography performed by operative cannulation of ileocolic vein.. Japanese Journal of Medicine, 1983, 22, 31-36.	0.1	2